參考文獻 |
1. Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer Statistics, 2021. CA Cancer J Clin 2021, 71:7-33.
2. Weigelt B, Reis-Filho JS: Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009, 6:718-730.
3. Gong Y, Liu YR, Ji P, Hu X, Shao ZM: Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep 2017, 7:45411.
4. Mao JH, Diest PJV, Perez-Losada J, Snijders AM: Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients. Sci Rep 2017, 7:12587.
5. Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, Gaba L, Diez M, Viladot M, Arance A, Munoz M: Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015, 24 Suppl 2:S26-35.
6. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V, De Placido S: Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010, 36 Suppl 3:S80-86.
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
8. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
9. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009, 115:423-428.
10. Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G: Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer 2020, 6:54.
11. Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, et al: Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med 2019, 11.
12. Schleich S, Strassburger K, Janiesch PC, Koledachkina T, Miller KK, Haneke K, Cheng YS, Kuechler K, Stoecklin G, Duncan KE, Teleman AA: DENR-MCT-1 promotes translation re-initiation downstream of uORFs to control tissue growth. Nature 2014, 512:208-212.
13. Schleich S, Acevedo JM, Clemm von Hohenberg K, Teleman AA: Identification of transcripts with short stuORFs as targets for DENR*MCTS1-dependent translation in human cells. Sci Rep 2017, 7:3722.
14. Bohlen J, Harbrecht L, Blanco S, Clemm von Hohenberg K, Fenzl K, Kramer G, Bukau B, Teleman AA: DENR promotes translation reinitiation via ribosome recycling to drive expression of oncogenes including ATF4. Nat Commun 2020, 11:4676.
15. Lomakin IB, Dmitriev SE, Steitz TA: Crystal structure of the DENR-MCT-1 complex revealed zinc-binding site essential for heterodimer formation. Proc Natl Acad Sci U S A 2019, 116:528-533.
16. Hsu HL, Shi B, Gartenhaus RB: The MCT-1 oncogene product impairs cell cycle checkpoint control and transforms human mammary epithelial cells. Oncogene 2005, 24:4956-4964.
17. Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL, Jr., Gartenhaus RB: MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res 2005, 65:10651-10656.
18. Shih HJ, Chu KL, Wu MH, Wu PH, Chang WW, Chu JS, Wang LH, Takeuchi H, Ouchi T, Hsu HL: The involvement of MCT-1 oncoprotein in inducing mitotic catastrophe and nuclear abnormalities. Cell Cycle 2012, 11:934-952.
19. Wu MH, Chen YA, Chen HH, Chang KW, Chang IS, Wang LH, Hsu HL: MCT-1 expression and PTEN deficiency synergistically promote neoplastic multinucleation through the Src/p190B signaling activation. Oncogene 2014, 33:5109-5120.
20. Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, Tung YC, Hsu HL: MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer 2019, 18:42.
21. Tseng HY, Chen YA, Jen J, Shen PC, Chen LM, Lin TD, Wang YC, Hsu HL: Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression. Oncogenesis 2017, 6:e313.
22. Zorov DB, Juhaszova M, Sollott SJ: Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 2014, 94:909-950.
23. Turrens JF: Mitochondrial formation of reactive oxygen species. J Physiol 2003, 552:335-344.
24. Murphy MP: How mitochondria produce reactive oxygen species. Biochem J 2009, 417:1-13.
25. Mailloux RJ, Harper ME: Mitochondrial proticity and ROS signaling: lessons from the uncoupling proteins. Trends Endocrinol Metab 2012, 23:451-458.
26. Becuwe P, Ennen M, Klotz R, Barbieux C, Grandemange S: Manganese superoxide dismutase in breast cancer: from molecular mechanisms of gene regulation to biological and clinical significance. Free Radic Biol Med 2014, 77:139-151.
27. Wang Y, Branicky R, Noe A, Hekimi S: Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol 2018, 217:1915-1928.
28. Hart PC, Ratti BA, Mao M, Ansenberger-Fricano K, Shajahan-Haq AN, Tyner AL, Minshall RD, Bonini MG: Caveolin-1 regulates cancer cell metabolism via scavenging Nrf2 and suppressing MnSOD-driven glycolysis. Oncotarget 2016, 7:308-322.
29. Velichkova M, Hasson T: Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol Cell Biol 2005, 25:4501-4513.
30. Menegon S, Columbano A, Giordano S: The Dual Roles of NRF2 in Cancer. Trends Mol Med 2016, 22:578-593.
31. Sporn MB, Liby KT: NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012, 12:564-571.
32. Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, Zhang DD: Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res 2014, 74:7430-7441.
33. Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, et al: Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 2013, 51:618-631.
34. Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F, Hayes DN, Major MB: Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res 2013, 73:2199-2210.
35. Kattan Z, Minig V, Leroy P, Dauca M, Becuwe P: Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res Treat 2008, 108:203-215.
36. Venkataraman S, Wagner BA, Jiang X, Wang HP, Schafer FQ, Ritchie JM, Patrick BC, Oberley LW, Buettner GR: Overexpression of manganese superoxide dismutase promotes the survival of prostate cancer cells exposed to hyperthermia. Free Radic Res 2004, 38:1119-1132.
37. Miriyala S, Spasojevic I, Tovmasyan A, Salvemini D, Vujaskovic Z, St Clair D, Batinic-Haberle I: Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta 2012, 1822:794-814.
38. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP: Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001, 276:4588-4596.
39. Murphy MP, Smith RA: Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007, 47:629-656.
40. Smith RA, Murphy MP: Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 2010, 1201:96-103.
41. Rao VA, Klein SR, Bonar SJ, Zielonka J, Mizuno N, Dickey JS, Keller PW, Joseph J, Kalyanaraman B, Shacter E: The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone. J Biol Chem 2010, 285:34447-34459.
42. Porporato PE, Payen VL, Perez-Escuredo J, De Saedeleer CJ, Danhier P, Copetti T, Dhup S, Tardy M, Vazeille T, Bouzin C, et al: A mitochondrial switch promotes tumor metastasis. Cell Rep 2014, 8:754-766.
43. Williamson J, Hughes CM, Cobley JN, Davison GW: The mitochondria-targeted antioxidant MitoQ, attenuates exercise-induced mitochondrial DNA damage. Redox Biol 2020, 36:101673.
44. Chang Q, Daly L, Bromberg J: The IL-6 feed-forward loop: a driver of tumorigenesis. Semin Immunol 2014, 26:48-53.
45. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
46. Johnson DE, O′Keefe RA, Grandis JR: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 2018, 15:234-248.
47. Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T: Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 2020, 16:335-345.
48. Han Q, Guo M, Zheng Y, Zhang Y, De Y, Xu C, Zhang L, Sun R, Lv Y, Liang Y, et al: Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Pharmacol 2020, 11:615972.
49. Kishimoto T: Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006, 8 Suppl 2:S2.
50. Scheinecker C, Smolen J, Yasothan U, Stoll J, Kirkpatrick P: Tocilizumab. Nat Rev Drug Discov 2009, 8:273-274.
51. Alraouji NN, Aboussekhra A: Tocilizumab inhibits IL-8 and the proangiogenic potential of triple negative breast cancer cells. Mol Carcinog 2021, 60:51-59.
52. Alraouji NN, Al-Mohanna FH, Ghebeh H, Arafah M, Almeer R, Al-Tweigeri T, Aboussekhra A: Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Mol Carcinog 2020, 59:1041-1051.
53. Jin K, Pandey NB, Popel AS: Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Res 2018, 20:54.
54. Thyagarajan A, Sahu RP: Potential Contributions of Antioxidants to Cancer Therapy: Immunomodulation and Radiosensitization. Integr Cancer Ther 2018, 17:210-216.
55. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252.
56. Balkwill FR, Capasso M, Hagemann T: The tumor microenvironment at a glance. J Cell Sci 2012, 125:5591-5596.
57. Shi C, Pamer EG: Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011, 11:762-774.
58. Alvey CM, Spinler KR, Irianto J, Pfeifer CR, Hayes B, Xia Y, Cho S, Dingal P, Hsu J, Smith L, et al: SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors. Curr Biol 2017, 27:2065-2077 e2066.
59. Argyle D, Kitamura T: Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors. Front Immunol 2018, 9:2629.
60. Nagarsheth N, Wicha MS, Zou W: Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 2017, 17:559-572.
61. Wynn TA, Chawla A, Pollard JW: Macrophage biology in development, homeostasis and disease. Nature 2013, 496:445-455.
62. Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z: Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci 2019, 26:78.
63. Aras S, Zaidi MR: TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer 2017, 117:1583-1591.
64. Jakubzick CV, Randolph GJ, Henson PM: Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol 2017, 17:349-362.
65. Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, et al: Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer Cell 2019, 35:588-602 e510.
66. Viola A, Munari F, Sanchez-Rodriguez R, Scolaro T, Castegna A: The Metabolic Signature of Macrophage Responses. Front Immunol 2019, 10:1462.
67. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, et al: Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013, 496:238-242.
68. Tan Z, Xie N, Cui H, Moellering DR, Abraham E, Thannickal VJ, Liu G: Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. J Immunol 2015, 194:6082-6089.
69. Van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, Luque-Martin R, Chen HJ, Boshuizen MC, Ahmed M, et al: Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages. Cell Rep 2016, 17:684-696.
70. Zhang Y, Choksi S, Chen K, Pobezinskaya Y, Linnoila I, Liu ZG: ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res 2013, 23:898-914.
71. Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer JP, Ho PY, McKenna KM, Cheshier S, Zhang M, Guo N, Gip P, et al: Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci U S A 2015, 112:2145-2150.
72. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al: PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017, 545:495-499.
73. Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL: CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 2019, 572:392-396.
74. Plebanek MP, Angeloni NL, Vinokour E, Li J, Henkin A, Martinez-Marin D, Filleur S, Bhowmick R, Henkin J, Miller SD, et al: Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche. Nat Commun 2017, 8:1319.
75. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
76. Stewart DA, Yang Y, Makowski L, Troester MA: Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages. Mol Cancer Res 2012, 10:727-738.
77. Gorelik R, Gautreau A: Quantitative and unbiased analysis of directional persistence in cell migration. Nat Protoc 2014, 9:1931-1943.
78. Benner B, Scarberry L, Suarez-Kelly LP, Duggan MC, Campbell AR, Smith E, Lapurga G, Jiang K, Butchar JP, Tridandapani S, et al: Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. J Immunother Cancer 2019, 7:140.
79. Cassetta L, Noy R, Swierczak A, Sugano G, Smith H, Wiechmann L, Pollard JW: Isolation of Mouse and Human Tumor-Associated Macrophages. Adv Exp Med Biol 2016, 899:211-229.
80. Szatrowski TP, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991, 51:794-798.
81. Mohanty JG, Jaffe JS, Schulman ES, Raible DG: A highly sensitive fluorescent micro-assay of H2O2 release from activated human leukocytes using a dihydroxyphenoxazine derivative. J Immunol Methods 1997, 202:133-141.
82. Spitz DR, Oberley LW: Measurement of MnSOD and CuZnSOD activity in mammalian tissue homogenates. Curr Protoc Toxicol 2001, Chapter 7:Unit7 5.
83. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010, 123:725-731.
84. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
85. Al Haq AT, Tseng HY, Chen LM, Wang CC, Hsu HL: Targeting prooxidant MnSOD effect inhibits triple-negative breast cancer (TNBC) progression and M2 macrophage functions under the oncogenic stress. Cell Death Dis 2022, 13:49.
86. Chan SH, Huang WC, Chang JW, Chang KJ, Kuo WH, Wang MY, Lin KY, Uen YH, Hou MF, Lin CM, et al: MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis. Oncogene 2014, 33:4496-4507.
87. Papadopoulos E, Jenni S, Kabha E, Takrouri KJ, Yi T, Salvi N, Luna RE, Gavathiotis E, Mahalingam P, Arthanari H, et al: Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G. Proc Natl Acad Sci U S A 2014, 111:E3187-3195.
88. Chomarat P, Banchereau J, Davoust J, Palucka AK: IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000, 1:510-514.
89. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM: Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947.
90. Montano MA, da Cruz IB, Duarte MM, Krewer Cda C, da Rocha MI, Manica-Cattani MF, Soares FA, Rosa G, Maris AF, Battiston FG, et al: Inflammatory cytokines in vitro production are associated with Ala16Val superoxide dismutase gene polymorphism of peripheral blood mononuclear cells. Cytokine 2012, 60:30-33.
91. Al Haq AT TH, Yang PP, Chen LM, Chen YA, Weng YS, Shen PC, Lai, YC, Hung WC, Wang LH, Hsu HL: Targeting the Positive-Feedback Nexuses of MCT-1/IL-6/CXCL7/PD-L1 Prevent Recurrence and Metastasis of Triple-negative Breast Cancer (TNBC) in the Xenograft Mice (manuscript in preparation). 2022.
92. Lenaz G, Fato R, Genova ML, Bergamini C, Bianchi C, Biondi A: Mitochondrial Complex I: structural and functional aspects. Biochim Biophys Acta 2006, 1757:1406-1420.
93. Ansenberger-Fricano K, Ganini D, Mao M, Chatterjee S, Dallas S, Mason RP, Stadler K, Santos JH, Bonini MG: The peroxidase activity of mitochondrial superoxide dismutase. Free Radic Biol Med 2013, 54:116-124.
94. Vidimar V, Gius D, Chakravarti D, Bulun SE, Wei JJ, Kim JJ: Dysfunctional MnSOD leads to redox dysregulation and activation of prosurvival AKT signaling in uterine leiomyomas. Sci Adv 2016, 2:e1601132.
95. Ganini D, Santos JH, Bonini MG, Mason RP: Switch of Mitochondrial Superoxide Dismutase into a Prooxidant Peroxidase in Manganese-Deficient Cells and Mice. Cell Chem Biol 2018, 25:413-425 e416.
96. James AM, Sharpley MS, Manas AR, Frerman FE, Hirst J, Smith RA, Murphy MP: Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem 2007, 282:14708-14718.
97. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 2020, 48:W509-W514.
98. Li F, Wang H, Huang C, Lin J, Zhu G, Hu R, Feng H: Hydrogen peroxide contributes to the manganese superoxide dismutase promotion of migration and invasion in glioma cells. Free Radic Res 2011, 45:1154-1161.
99. Dhar SK, Tangpong J, Chaiswing L, Oberley TD, St Clair DK: Manganese superoxide dismutase is a p53-regulated gene that switches cancers between early and advanced stages. Cancer Res 2011, 71:6684-6695.
100. Hart PC, Mao M, de Abreu AL, Ansenberger-Fricano K, Ekoue DN, Ganini D, Kajdacsy-Balla A, Diamond AM, Minshall RD, Consolaro ME, et al: MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer. Nat Commun 2015, 6:6053.
101. He C, Danes JM, Hart PC, Zhu Y, Huang Y, de Abreu AL, O′Brien J, Mathison AJ, Tang B, Frasor JM, et al: SOD2 acetylation on lysine 68 promotes stem cell reprogramming in breast cancer. Proc Natl Acad Sci U S A 2019, 116:23534-23541.
102. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
103. Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Yang H, Negri GL, von Karstedt S, Lockwood WW, Schaffer P, et al: Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A 2019, 116:9433-9442.
104. Zhu Y, Zou X, Dean AE, Brien JO, Gao Y, Tran EL, Park SH, Liu G, Kieffer MB, Jiang H, et al: Lysine 68 acetylation directs MnSOD as a tetrameric detoxification complex versus a monomeric tumor promoter. Nat Commun 2019, 10:2399.
105. Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, Ichimiya M, Sengupta S, Mechanic L, Okamura S, et al: p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 2004, 64:2350-2356.
106. Thomas C, Mackey MM, Diaz AA, Cox DP: Hydroxyl radical is produced via the Fenton reaction in submitochondrial particles under oxidative stress: implications for diseases associated with iron accumulation. Redox Rep 2009, 14:102-108.
107. Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S, Xiong Y: Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep 2011, 12:534-541.
108. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes McDonald W, et al: Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 2010, 40:893-904.
109. Borgstahl GE, Parge HE, Hickey MJ, Beyer WF, Jr., Hallewell RA, Tainer JA: The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles. Cell 1992, 71:107-118.
110. Schieber M, Chandel NS: ROS function in redox signaling and oxidative stress. Curr Biol 2014, 24:R453-462.
111. Kim YM, Kim SJ, Tatsunami R, Yamamura H, Fukai T, Ushio-Fukai M: ROS-induced ROS release orchestrated by Nox4, Nox2, and mitochondria in VEGF signaling and angiogenesis. Am J Physiol Cell Physiol 2017, 312:C749-C764.
112. Brown CO, Salem K, Wagner BA, Bera S, Singh N, Tiwari A, Choudhury A, Buettner GR, Goel A: Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase. Biochem J 2012, 444:515-527.
113. Wruck CJ, Streetz K, Pavic G, Gotz ME, Tohidnezhad M, Brandenburg LO, Varoga D, Eickelberg O, Herdegen T, Trautwein C, et al: Nrf2 induces interleukin-6 (IL-6) expression via an antioxidant response element within the IL-6 promoter. J Biol Chem 2011, 286:4493-4499.
114. Formentini L, Santacatterina F, Nunez de Arenas C, Stamatakis K, Lopez-Martinez D, Logan A, Fresno M, Smits R, Murphy MP, Cuezva JM: Mitochondrial ROS Production Protects the Intestine from Inflammation through Functional M2 Macrophage Polarization. Cell Rep 2017, 19:1202-1213.
115. Griess B, Mir S, Datta K, Teoh-Fitzgerald M: Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat3 suppression. Free Radic Biol Med 2020, 147:48-60.
116. Erttmann SF, Gekara NO: Hydrogen peroxide release by bacteria suppresses inflammasome-dependent innate immunity. Nat Commun 2019, 10:3493.
117. Hara-Chikuma M, Tanaka M, Verkman AS, Yasui M: Inhibition of aquaporin-3 in macrophages by a monoclonal antibody as potential therapy for liver injury. Nat Commun 2020, 11:5666.
118. Troyano A, Sancho P, Fernandez C, de Blas E, Bernardi P, Aller P: The selection between apoptosis and necrosis is differentially regulated in hydrogen peroxide-treated and glutathione-depleted human promonocytic cells. Cell Death Differ 2003, 10:889-898.
119. Brown RAM, Richardson KL, Kabir TD, Trinder D, Ganss R, Leedman PJ: Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology. Front Oncol 2020, 10:476.
120. Vasudevan D, Neuman SD, Yang A, Lough L, Brown B, Bashirullah A, Cardozo T, Ryoo HD: Translational induction of ATF4 during integrated stress response requires noncanonical initiation factors eIF2D and DENR. Nat Commun 2020, 11:4677.
121. Vecchi C, Montosi G, Zhang K, Lamberti I, Duncan SA, Kaufman RJ, Pietrangelo A: ER stress controls iron metabolism through induction of hepcidin. Science 2009, 325:877-880.
122. van Rooijen N, Hendrikx E: Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol 2010, 605:189-203.
123. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA: Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006, 95:272-281.
124. Nagy A, Lanczky A, Menyhart O, Gyorffy B: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 2018, 8:9227. |